Abliva AB (OSTO:ABLI) ROCE % : -120.62% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Abliva AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abliva AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -120.62%.

Abliva AB ROCE % Historical Data

The historical data trend for Abliva AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB ROCE % Chart

Abliva AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-68.39

-55.32

-189.57

-79.96

-80.90

Abliva AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-40.46	-40.88	-60.85	-116.92	-120.62

Abliva AB ROCE % Calculation

Abliva AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-95.442	/	( ( (183.829 - 19.007)	+	(87.499 - 16.357) )	/ 2 )
	=	-95.442	/	( (164.822	+	71.142)	/ 2 )
	=	-95.442	/	117.982
	=	-80.90 %

Abliva AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-100.976	/	( ( (109.003 - 12.719)	+	(87.499 - 16.357) )	/ 2 )
	=	-100.976	/	( ( 96.284	+	71.142 )	/ 2 )
	=	-100.976	/	83.713
	=	-120.62 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Abliva AB (OSTO:ABLI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abliva AB ROCE % Related Terms

Thank you for viewing the detailed overview of Abliva AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB (OSTO:ABLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NEVPF:USA NTP:Germany

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines